In January–November 2022, Russia imported 174.5 billion rubles’ worth of APIs (customs clearance and VAT included), down 3.9% from January–November 2021. In physical terms (tons), the growth rate was 19.8%, with 18,900 tons imported.

In January–November 2022, Russian manufacturers produced 629.1 billion rubles’ worth of ready-made drugs (manufacturer’s prices, VAT included), up 15.1% from the same period in 2021. In physical terms, the production volume was 3.81 billion packages, up 2.2% from January–November 2021. If calculated in minimum dosage units (MDU), 72.5 billion MDUs were produced, up 2.3% from the same period last year.

More than 55% of Russian doctors do not think mobilization has affected their workplace, according to a survey conducted by the RNC Pharma analyst company and the Medvestnik platform for doctors.

In January–November 2022, the sales of veterinary drugs in the Russian offline retail market were 18.8 billion RUB retail prices, VAT included), down 5.2% from the same period in 2021. The results could have been much worse if not for the activity in October–November 2022 compensating for the drop in consumption back in the spring and summer 2022. In physical terms, the sales were 123.4 million minimum dosage units (MDU), down 20.7%.

In Q1–Q3 2022, the online sales or reservations of pharmacy products (pharmaceutical drugs and parapharmaceuticals) in Russia were 213.4 billion rubles (end-user prices, VAT included), which is much higher than the total in 2021. The sales and reservations went up 50.7% (against 51.3% in Q1–Q2 2022). The growth rate is significantly more different from those seen due to the rush demand earlier this year—in particular, the sales in Q1 2022 grew 69.6%.

In January–October 2022, the sales of veterinary drugs in the Russian retail market were 17.5 billion RUB (retail prices, VAT included), down 5.5% from the same period in 2021. That is an obvious result of the rush demand in March, the flow of consumers to the online segment, as well as dropping household incomes. In physical terms, the sales were 113.4 million minimum dosage units (MDU), down 21%.